{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:06:09Z","timestamp":1794661569672,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01179-2","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:03:41Z","timestamp":1780477421000},"page":"964-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-9099","authenticated-orcid":false,"given":"Jack Y.","family":"Ghannam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-0568","authenticated-orcid":false,"given":"Jakob","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kovarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Schlueter-Kuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey G.","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Lim-Fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaquat","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-865X","authenticated-orcid":false,"given":"Geoffrey S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0887-8482","authenticated-orcid":false,"suffix":"III","given":"J. Thomas","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6831-4707","authenticated-orcid":false,"given":"McKayla","family":"Van Orden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6650-380X","authenticated-orcid":false,"given":"Andrew","family":"Gans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0560-2849","authenticated-orcid":false,"given":"Emma S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-6337","authenticated-orcid":false,"given":"Brian P.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-5074","authenticated-orcid":false,"given":"Laxmi","family":"Parida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-6141","authenticated-orcid":false,"given":"Shuqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-1670","authenticated-orcid":false,"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7733-600X","authenticated-orcid":false,"given":"Keith L.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Tirosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-0157","authenticated-orcid":false,"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol. 25, 799\u2013807 (2023).","journal-title":"Neuro Oncol."},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro Oncol."},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"1179_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa, J. R. et al. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat. Commun. 15, 10757 (2024).","journal-title":"Nat. Commun."},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1179_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722\u20134729 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41694-9","volume":"14","author":"I Noorani","year":"2023","unstructured":"Noorani, I. & de la Rosa, J. Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat. Commun. 14, 5909 (2023).","journal-title":"Nat. Commun."},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","volume":"27","author":"JB Iorgulescu","year":"2021","unstructured":"Iorgulescu, J. B. et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin. Cancer Res. 27, 276\u2013287 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326753","volume":"15","author":"AA Stepanenko","year":"2024","unstructured":"Stepanenko, A. A. Systemic and local immunosuppression in glioblastoma and its prognostic significance. Front. Immunol. 15, 1326753 (2024).","journal-title":"Front. Immunol."},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0165-5728(99)00203-9","volume":"100","author":"AR Dix","year":"1999","unstructured":"Dix, A. R., Brooks, W. H., Roszman, T. L. & Morford, L. A. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100, 216\u2013232 (1999).","journal-title":"J. Neuroimmunol."},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","volume":"24","author":"KI Woroniecka","year":"2018","unstructured":"Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. T-cell dysfunction in glioblastoma: applying a new framework. Clin. Cancer Res. 24, 3792\u20133802 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1179_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","volume":"6","author":"TM Johanns","year":"2016","unstructured":"Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6, 1230\u20131236 (2016).","journal-title":"Cancer Discov."},{"key":"1179_CR22","volume":"3","author":"S Sathornsumetee","year":"2021","unstructured":"Sathornsumetee, S., Nunta-aree, S. & Cheunsuchon, P. Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation. Neurooncol. Adv. 3, vdab093 (2021).","journal-title":"Neurooncol. Adv."},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517\u2013523 (2020).","journal-title":"Nature"},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 25, 462\u2013469 (2019).","journal-title":"Nat Med"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","volume":"2","author":"VA Arrieta","year":"2021","unstructured":"Arrieta, V. A. et al. ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2, 1372\u20131386 (2021).","journal-title":"Nat Cancer"},{"key":"1179_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56930-7","volume":"16","author":"S-P Weathers","year":"2025","unstructured":"Weathers, S.-P. et al. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I\/II trial. Nat. Commun. 16, 3950 (2025).","journal-title":"Nat. Commun."},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.annonc.2022.11.008","volume":"34","author":"K White","year":"2023","unstructured":"White, K. et al. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. Ann. Oncol. 34, 300\u2013314 (2023).","journal-title":"Ann. Oncol."},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia, E. P. et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab. Med. 141, 751\u2013758 (2017).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1179_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016195","volume":"6","author":"J Wei","year":"2011","unstructured":"Wei, J. et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS ONE 6, e16195 (2011).","journal-title":"PLoS ONE"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak, L. et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin. Cancer Res. 27, 1048\u20131057 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1158\/1078-0432.CCR-21-4064","volume":"28","author":"L Nayak","year":"2022","unstructured":"Nayak, L. et al. Circulating immune cell and outcome analysis from the phase II study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma. Clin. Cancer Res. 28, 2567\u20132578 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112\u2013120 (2019).","journal-title":"Nature"},{"key":"1179_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jnen\/nlad092","volume":"83","author":"N Nuechterlein","year":"2023","unstructured":"Nuechterlein, N., Shelbourn, A. & Cimino, P. J. Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes. J. Neuropathol. Exp. Neurol. 83, 53\u201357 (2023).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41576-023-00663-0","volume":"25","author":"K Krupina","year":"2024","unstructured":"Krupina, K., Goginashvili, A. & Cleveland, D. W. Scrambling the genome in cancer: causes and consequences of complex chromosome rearrangements. Nat. Rev. Genet 25, 196\u2013210 (2024).","journal-title":"Nat. Rev. Genet"},{"key":"1179_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das, A. et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat. Med. 28, 125\u2013135 (2022).","journal-title":"Nat. Med."},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","volume":"57","author":"A Spitzer","year":"2025","unstructured":"Spitzer, A. et al. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat. Genet. 57, 1168\u20131178 (2025).","journal-title":"Nat. Genet."},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"1179_CR39","doi-asserted-by":"publisher","unstructured":"Ghannam, J. Ghannam et al. extended methods V.2. protocols.io https:\/\/doi.org\/10.17504\/protocols.io.rm7vz49b5lx1\/v2 (2026).","DOI":"10.17504\/protocols.io.rm7vz49b5lx1\/v2"},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak, R. G. W. et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17, 98 (2010).","journal-title":"Cancer Cell"},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"109184","DOI":"10.1016\/j.isci.2024.109184","volume":"27","author":"H Bv","year":"2024","unstructured":"Bv, H. & Jolly, M. K. Proneural\u2013mesenchymal antagonism dominates the patterns of phenotypic heterogeneity in glioblastoma. iScience 27, 109184 (2024).","journal-title":"iScience"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32, 42\u201356 (2017).","journal-title":"Cancer Cell"},{"key":"1179_CR43","first-page":"363","volume":"21","author":"C Xu","year":"2024","unstructured":"Xu, C. et al. Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition. Cancer Biol. Med. 21, 363\u2013381 (2024).","journal-title":"Cancer Biol. Med."},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","volume":"39","author":"T Hara","year":"2021","unstructured":"Hara, T. et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39, 779\u2013792 (2021).","journal-title":"Cancer Cell"},{"key":"1179_CR45","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639\u2013655 (2022).","journal-title":"Cancer Cell"},{"key":"1179_CR46","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","volume":"187","author":"AC Greenwald","year":"2024","unstructured":"Greenwald, A. C. et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell 187, 2485\u20132501 (2024).","journal-title":"Cell"},{"key":"1179_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849 (2019).","journal-title":"Cell"},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","volume":"57","author":"M Nomura","year":"2025","unstructured":"Nomura, M. et al. The multilayered transcriptional architecture of glioblastoma ecosystems. Nat. Genet. 57, 1155\u20131167 (2025).","journal-title":"Nat. Genet."},{"key":"1179_CR49","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat. Cancer 3, 1534\u20131552 (2022).","journal-title":"Nat. Cancer"},{"key":"1179_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01122-x","volume":"14","author":"R Chanoch-Myers","year":"2022","unstructured":"Chanoch-Myers, R., Wider, A., Suva, M. L. & Tirosh, I. Correction: Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis. Genome Med. 14, 117 (2022).","journal-title":"Genome Med."},{"key":"1179_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","volume":"125","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma, E., Fugle, C. M., Wang, X. & Cheng, C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br. J. Cancer 125, 422\u2013432 (2021).","journal-title":"Br. J. Cancer"},{"key":"1179_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17186-5","volume":"11","author":"CP Couturier","year":"2020","unstructured":"Couturier, C. P. et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 11, 3406 (2020).","journal-title":"Nat. Commun."},{"key":"1179_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","volume":"2","author":"L Garofano","year":"2021","unstructured":"Garofano, L. et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat. Cancer 2, 141\u2013156 (2021).","journal-title":"Nat. Cancer"},{"key":"1179_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv2881","volume":"17","author":"AL Ling","year":"2025","unstructured":"Ling, A. L. et al. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci. Transl. Med. 17, eadv2881 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1179_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry, E. M. et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat. Med. 29, 158\u2013169 (2023).","journal-title":"Nat. Med."},{"key":"1179_CR56","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.0308531101","volume":"101","author":"J-P Brunet","year":"2004","unstructured":"Brunet, J.-P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA 101, 4164\u20134169 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1179_CR57","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"1179_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1179_CR59","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"1179_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271\u2013281 (2018).","journal-title":"Cell Syst."},{"key":"1179_CR61","first-page":"656","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. BLAT\u2014the BLAST-like alignment tool. Genome Res. 12, 656\u2013664 (2002).","journal-title":"Genome Res."},{"key":"1179_CR62","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ng.3343","volume":"47","author":"MD Stachler","year":"2015","unstructured":"Stachler, M. D. et al. Paired exome analysis of Barrett\u2019s esophagus and adenocarcinoma. Nat. Genet. 47, 1047\u20131055 (2015).","journal-title":"Nat. Genet."},{"key":"1179_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"1179_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"1179_CR65","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318\u20131330 (2020).","journal-title":"Science"},{"key":"1179_CR66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1179_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"1179_CR68","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/bioinformatics\/btab135","volume":"37","author":"A Graubert","year":"2021","unstructured":"Graubert, A., Aguet, F., Ravi, A., Ardlie, K. G. & Getz, G. RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics 37, 3048\u20133050 (2021).","journal-title":"Bioinformatics"},{"key":"1179_CR69","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","volume":"20","author":"SJ Fleming","year":"2023","unstructured":"Fleming, S. J. et al. Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender. Nat. Methods 20, 1323\u20131335 (2023).","journal-title":"Nat. Methods"},{"key":"1179_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1179_CR71","doi-asserted-by":"publisher","unstructured":"Ghannam, J., Weiss, J., Merrell, D. & Iorgulescu, J. B. Code and data for the Ghannam et al. glioblastoma\/ICB manuscript. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17460015 (2025).","DOI":"10.5281\/zenodo.17460015"}],"updated-by":[{"DOI":"10.1038\/s43018-026-01197-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000}}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01179-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:03:47Z","timestamp":1782482627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01179-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01179-2","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43018-026-01197-0","URL":"https:\/\/doi.org\/10.1038\/s43018-026-01197-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.J.W. holds equity from BioNTech and receives research funding from Pharmacyclics; she is also on the scientific advisory boards of Adventris, Nature\u2019s Toolbox, Repertoire and Aethon Therapeutics. G.G. receives research funds from IBM, Pharmacyclics\/AbbVie, Bayer, Genentech, Calico, Ultima Genomics and Inocras and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye and MinimuMM-seq. G.G. is a founder and consultant and holds privately held equity in Scorpion Therapeutics; he is also a founder of and holds privately held equity in PreDICTA Biosciences. G.G. has also consulted for Merck. R.Y.H. consults for Nuvation Bio, Servier and Telix and is on the scientific advisory board of Vysioneer. D.A.R. has received financial compensation for consultancy or advisory board participation from AnHeart Pharmaceuticals, Aptitude Health, BlueRock Therapeutics, CeCaVa & Co., Chimeric Therapeutics, Elsevier, F. Hoffmann La-Roche, Genenta Science, Inovio, Insightec, Janssen, Jupiter Life Sciences Consulting, Kintara, Kiyatec, Johnson & Johnson Pharma, Lumanity, Menari Stemline, Miltenyi Biomedicine, Neuvogen, Novocure, Paradigm Medical Communications, Putnam Inizii Associates, Sumitomo Dainippon Pharma Oncology, Servier, Triangle Insights Group, Vivacitas Oncology and WebMD. D.A.R. serves as a member of a data safety monitoring board for ImVax and CeCaVa and owns stock in AnHeart Therapeutics and Bionaut Labs. E.A.C. is cofounder and holds equity in Ternalys Therapeutics, holds equity in Bionaut Technologies and Seneca Therapeutics and consults for Theriva, Genenta. P.Y.W. has received research funding from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, Eli Lilly, Erasca, Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier and VBI Vaccines and honoraria for consulting from AstraZeneca, Black Diamond, Bristol Myers Squibb, Chimerix, Eli Lilly, Erasca, Global Coalition for Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier and VBI Vaccines. D.N. has stock in Madrigal Pharmaceuticals. I.T. is an advisory board member of Immunitas Therapeutics and scientific cofounder of Cellyrix Therapeutics. K.L.L. holds equity in Travera and has received consulting fees from Travera, Servier, BMS, LEK and Blaze Biosciences and research funds from BMS and Lilly. R.R. consults (advisory board participation) for Servier Pharmaceuticals and Telix Pharmaceuticals and serves as a consultant (unpaid) for NH TherAguix. The other authors declare no competing interests related to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}